|
04 Oct 2025 |
Torrent Pharma
|
Consensus Share Price Target
|
3514.70 |
3929.42 |
- |
11.80 |
buy
|
|
|
|
|
23 Oct 2023
|
Torrent Pharma
|
Sharekhan
|
3514.70
|
1972.00
|
1889.65
(86.00%)
|
Target met |
Hold
|
|
|
|
|
23 Oct 2023
|
Torrent Pharma
|
Prabhudas Lilladhar
|
3514.70
|
2250.00
|
1877.30
(87.22%)
|
Target met |
Buy
|
|
|
|
|
08 Aug 2023
|
Torrent Pharma
|
ICICI Securities Limited
|
3514.70
|
2130.00
|
2051.40
(71.33%)
|
Target met |
Hold
|
|
|
Torrent’s Q1FY24 performance was boosted by the acquisition of Curatio in India, while delay in shipments derailed growth in Brazil (sales of ~INR 250mn in Q1). Organic growth in domestic branded biz is estimated at ~8-9% led by price rise and new launches.
|
|
07 Aug 2023
|
Torrent Pharma
|
Motilal Oswal
|
3514.70
|
1960.00
|
2051.40
(71.33%)
|
Target met |
Neutral
|
|
|
|
|
05 Jun 2023
|
Torrent Pharma
|
Geojit BNP Paribas
|
3514.70
|
1933.00
|
1775.25
(97.98%)
|
Target met |
Hold
|
|
|
|
|
01 Jun 2023
|
Torrent Pharma
|
StoxBox - BP Wealth
|
3514.70
|
|
1774.80
(98.03%)
|
|
Results Update
|
|
|
Torrent Pharma reported a revenue growth of 16.9% YoY / flat QoQ to Rs. 24,910 mn and was marginally above market expectations of Rs. 24,320 mn. Domestic revenue grew 21.6% YoY, aided by strong performance of new launches in chronic therapies and integration of Curatio.
|
|
31 May 2023
|
Torrent Pharma
|
ICICI Securities Limited
|
3514.70
|
1645.00
|
1713.55
(105.11%)
|
|
Hold
|
|
|
Torrent Pharma’s (Torrent) Q4FY23 India performance was boosted by acquisition of Curatio (~5% of its India sales) while its gross margin at 71.7% was better due to solid traction in the branded generic business.
|
|
31 May 2023
|
Torrent Pharma
|
ICICI Direct
|
3514.70
|
2010.00
|
1835.80
(91.45%)
|
Target met |
Buy
|
|
|
|
|
31 May 2023
|
Torrent Pharma
|
Prabhudas Lilladhar
|
3514.70
|
1900.00
|
1835.80
(91.45%)
|
Target met |
Buy
|
|
|
|
|
17 Mar 2023
|
Torrent Pharma
|
Sharekhan
|
3514.70
|
1788.00
|
1534.00
(129.12%)
|
Target met |
Buy
|
|
|
|